BCL2L1 and neoplasm: This profile accounted for both the early anti-tumor activity that was observed in CLL (11) and the dose-limiting toxicity of thrombocytopenia, with BCL-2 inhibition driving the former and BCL-XL inhibition the latter (12, 13).